Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur J Pharmacol ; 504(3): 155-67, 2004 Nov 19.
Artigo em Inglês | MEDLINE | ID: mdl-15541417

RESUMO

The objective of this study was to pharmacologically characterize bradykinin receptors, a component of the kallikrein-kinin system, in normal human prostate cells. In primary cultured human prostate stromal cells, bradykinin, but not [des-Arg9]bradykinin or [des-Arg10]kallidin, produced calcium mobilization or inositol phosphates accumulation with potencies (pEC50) of 8.8+/-0.2 and 8.2+/-0.2, respectively. This was consistent with abundance of bradykinin B2 mRNA over bradykinin B1 mRNA in prostate stromal cells. Although the prostate epithelial cells (prostate epithelium, BPH-1, and PC-3) expressed mRNA for bradykinin B2 receptors (albeit in lesser amounts than stromal cells), bradykinin was not functionally efficacious in the epithelial cells. Increasing concentrations of D-arginyl-L-arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-D-1,2,3,4-tetrahhydro-3-isoquinolinecarbonyl-L-(2alpha,3beta,7alphabeta)-octahydro-1H-indole-2-carbonyl-L-arginine (HOE-140), a bradykinin B2-selective peptide antagonist, attenuated bradykinin concentration-response curves in human prostate stromal cells with apparent estimate of affinity similar to that for the human bradykinin B2 receptor. Bradykinin (10 nM) caused proliferation of prostate stromal cells and phosphorylated extracellular signal-regulated kinases (ERK-1 and ERK-2) that were blocked by HOE-140 (1 microM). This study demonstrated that, in primary cultures of normal human prostate stromal cells, bradykinin activates bradykinin B2 receptors that may play a significant role in proliferation via activation of ERK-1/2 pathways.


Assuntos
Próstata/metabolismo , Receptor B2 da Bradicinina/metabolismo , Adolescente , Adulto , Western Blotting , Cálcio/metabolismo , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Colorimetria , Ativação Enzimática/efeitos dos fármacos , Células Epiteliais/efeitos dos fármacos , Células Epiteliais/metabolismo , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , Humanos , Imuno-Histoquímica , Fosfatos de Inositol/metabolismo , Masculino , Próstata/efeitos dos fármacos , Hiperplasia Prostática/metabolismo , Neoplasias da Próstata/metabolismo , RNA Mensageiro/biossíntese , RNA Mensageiro/genética , Receptor B1 da Bradicinina/efeitos dos fármacos , Receptor B1 da Bradicinina/metabolismo , Receptor B2 da Bradicinina/efeitos dos fármacos , Reação em Cadeia da Polimerase Via Transcriptase Reversa
2.
Br J Pharmacol ; 142(2): 297-304, 2004 May.
Artigo em Inglês | MEDLINE | ID: mdl-15155537

RESUMO

The objective of this study was to characterize pharmacologically bradykinin (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg, BK) receptors in the canine prostate. Primary cultures of canine prostate stromal (PS) and epithelial cells (PE) were established and then characterized using cell-specific antibodies (actin, vimentin and cytokeratin). Cultured cells were assayed for BK receptors using fluorometric imaging plate reader assays. In addition, isolated strips of the canine prostate were studied for BK-induced isometric contraction. PS cells were labeled only with anti-actin and -vimentin antibodies, while the anti-cytokeratin antibodies labeled only the PE cells. In cultured prostate cells, the BK receptor 2 (B2)-preferring agonist BK induced mobilization of intracellular Ca(2+) in a concentration-dependent manner with potencies (log[EC(50)]mid R:PE, pEC(50)) of 8.72+/-0.12 in PS and 8.75+/-0.06 in PE cells. In contrast, the BK receptor 1 (B1)-selective agonist [des-Arg(9)]BK (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe) did not elicit any significant effect (pEC(50)<5) on Ca(2+) responses. BK agonism (10 nm) was inhibited by HOE-140 (D-arginyl-L-arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-D-1,2,3,4-tetrahhydro-3-isoquinolinecarbonyl-L-(2a,3b,7ab)-octahydro-1H-indole-2-carbonyl-L-arginine), a B2-selective antagonist, with a log[IC(50)] (pIC(50)) of 8.11+/-0.19 and 9.23+/-0.20 in PS and PE cells, respectively. [des-Arg(10)]HOE-140 (d-arginyl-l-arginlyl-l-prolyl-trans-4-hydroxy-l-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-(2a, 3b,7ab)-octahydro-1H-indole-2-carbonyl), a B1-selective antagonist, displayed weak antagonism with pIC(50) values of 4.87+/-0.23 and 6.38+/-0.16 in PS and PE cells, respectively. Isolated tissue strips of the canine prostate contracted to BK (10 microm) but not to [des-Arg(9)]BK (10 microm). BK-induced contractility was attenuated by HOE-140 (1 microm). In conclusion, canine prostates express functional B2 receptors, with no apparent B1 receptor subtypes.


Assuntos
Antagonistas de Receptor B2 da Bradicinina , Bradicinina/análogos & derivados , Próstata/efeitos dos fármacos , Receptor B2 da Bradicinina/agonistas , Sequência de Aminoácidos/fisiologia , Animais , Bradicinina/metabolismo , Bradicinina/farmacologia , Células CHO , Cálcio/metabolismo , Células Cultivadas , Cricetinae , Cães , Relação Dose-Resposta a Droga , Masculino , Técnicas de Cultura de Órgãos , Próstata/citologia , Próstata/metabolismo , Receptor B2 da Bradicinina/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...